ArticleBiosensors & bioelectronics2014
Quantification of cardiac biomarkers using label-free and multiplexed gold nanorod bioprobes for myocardial infarction diagnosis.
Article in Biosensors & bioelectronics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 57 citations in OpenAlex.
- Recent trends and impact of localized surface plasmon resonance (LSPR) and surface-enhanced Raman spectroscopy (SERS) in modern analysis.Journal of pharmaceutical analysis · 2024Review
- Gold nanorods as biocompatible nano-agents for the enhanced photothermal therapy in skin disorders.Journal of biomedical research · 2024Article
- Application of biomedical materials in the diagnosis and treatment of myocardial infarction.Journal of nanobiotechnology · 2023Review
- Fabrication and Characterization of Acute Myocardial Infarction Myoglobin Biomarker Based on Chromium-Doped Zinc Oxide Nanoparticles.Biosensors · 2022Article
- Cardiovascular biomarkers in body fluids: progress and prospects in optical sensors.Biophysical reviews · 2022Review
- Polymer-Peptide Modified Gold Nanorods to Improve Cell Conjugation and Cell labelling for Stem Cells Photoacoustic Imaging.Diagnostics (Basel, Switzerland) · 2021Article
- Gold Nanorods for LSPR Biosensing: Synthesis, Coating by Silica, and Bioanalytical Applications.Biosensors · 2020Review
- Nanosensors based on LSPR are able to serologically differentiate dengue from Zika infections.Scientific reports · 2020Article
- Rapid, multiplexed detection of biomolecules using electrically distinct hydrogel beads.Lab on a chip · 2020Article
- Nanoscale Technologies for Prevention and Treatment of Heart Failure: Challenges and Opportunities.Chemical reviews · 2019Review
- On/off-switchable LSPR nano-immunoassay for troponin-T.Scientific reports · 2017Article
- Silk-Encapsulated Plasmonic Biochips with Enhanced Thermal Stability.ACS applied materials & interfaces · 2016Article
- Peptide Functionalized Gold Nanorods for the Sensitive Detection of a Cardiac Biomarker Using Plasmonic Paper Devices.Scientific reports · 2015Article
- Gold Nanoparticles for In Vitro Diagnostics.Chemical reviews · 2015Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Gold nanorod (GNR) is an attractive optical transducer for label-free biosensing owing to the localized surface plasmon resonance (LSPR) which is highly sensitive to the dielectric constant of the surrounding medium modulated by biological bindings. By adjusting the nanorod aspect ratio (length to width ratio), desired absorption wavelength can be continuously tuned from 600 to 1100 nm. Here we demonstrated a linear relationship between the aspect ratio and the LSPR peak wavelength. Taking advantage of this tunability feature, we developed a multiplexed GNR sensor by combining nanorods with distinct LSPR wavelengths. Specifically, GNRs of AR 2.1 and 4.2 exhibiting longitudinal plasmonic band of 640 and 830 nm, respectively, were functionalized with specific antibody. Concentrations of multiple analytes were measured by correlating to the spectral shift at the distinct plasmon band maxima upon specific binding. The practical use of this mixed bioprobes for simultaneous quantification of cardiac biomarkers (myoglobin and cardiac troponin I) in the clinically significant sensing range was described. The LSPR red shift magnitude is linearly proportional to the increase in the target analyte concentration (R(2)=0.98). The calibration curve can clearly differentiate varying biomarker amounts with a high specificity. For multiplexed biosensing, the plasmon shift at the dedicated peak wavelength can be specifically correlated with spiked biomarker for simultaneous detection in the sample mixture. This technology can be further transformed onto miniaturized biochips based on the nanosized optical transducer to allow point-of-care blood testing for risk stratifications of cardiac patients in clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.